Browse the evidence

Equating total load lifted (volume) during acute resistance training renders exercise intensity (35% vs 70% 1RM) irrelevant for acute neurotrophic factor (BDNF, NGF) responses.

If you want to stimulate brain-derived neurotrophic factors (BDNF) through resistance training, you do not need to lift heavy weights. As long as you lift the same total amount of weight (volume) as someone lifting heavy, your brain gets the same acute signal. This allows for joint-friendly training using lighter loads (e.g., 35% 1RM) to achieve similar neurotrophic outcomes to heavier loads (70% 1RM).

Prolonged use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for 3 years or more can enhance beta-cell function.

For those who cannot or will not undergo surgery or strict dieting, long-term GLP-1 agonist therapy (3+ years) may help preserve your pancreas's insulin-producing capacity. This is a disease-modifying effect, not just glucose lowering.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

GLP-1 receptor agonist therapy causes a significant increase in resting heart rate (RHR) during the initial 12 weeks of treatment, which is primarily mediated by a reduction in heart rate variability (HRV).

If you start a GLP-1 medication (like semaglutide or tirzepatide), expect your resting heart rate to increase by about 3 beats per minute over the first 3 months. This is a normal, mediated response involving your autonomic nervous system (HRV), not necessarily a sign of heart damage. If you use a wearable, track this trend, but consult your doctor if the increase is extreme or accompanied by other symptoms.

Bariatric surgery prevents the onset of type 2 diabetes in obese patients without preexisting diabetes, with incidence rates significantly lower than non-surgical obese controls.

If you are obese but do not yet have diabetes, bariatric surgery can significantly reduce your risk of developing it over the next 15 years compared to lifestyle changes alone. While surgery is invasive, the long-term data shows it is a highly effective preventive strategy for those with severe obesity.

SGLT2 inhibitors improve vascular function by reducing arterial stiffness, improving endothelial function (flow-mediated dilation), and reducing inflammation and oxidative stress.

These drugs don't just lower sugar; they physically improve the health of your blood vessels by making them more flexible and reducing the chemical stress (inflammation/oxidative stress) that damages them over time.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.

Intermittent Hypoxia (IH) is a key pathogenic factor in OSA that drives cardiovascular and metabolic disease through vascular remodelling, atherosclerosis, and insulin resistance, independent of obesity.

The repeated drops in oxygen during sleep (Intermittent Hypoxia) are what actually damage your heart and metabolism, not just the breathing stops themselves. Managing OSA is crucial to prevent this cycle of damage.

Lifestyle interventions (diet and exercise) alone are insufficient for the majority (80%) of patients with obesity and fail to produce sustained weight loss without addressing the underlying biological disease mechanisms.

If you have obesity, relying solely on diet and exercise is likely to fail for you because your body's biological regulation of weight is disrupted. This is not your fault. You need medical treatment (pharmacotherapy or surgery) to address the biology first; lifestyle changes are only useful for maintenance after the biological drivers are managed.

Cholecystokinin (CCK) acts as a primary intestinal satiety signal that regulates food intake via CCK1 receptors on afferent vagal fibers, with its secretion dynamics altered by bariatric surgery but remaining largely unchanged in obesity.

CCK is your body's natural 'fullness' signal from the gut. In obesity, this signal isn't broken; levels are normal. However, bariatric surgery can enhance this signal significantly. Focus on dietary strategies that naturally stimulate CCK release (like protein/fat intake) rather than assuming a hormonal defect.

GLP-1 receptor agonists, SGLT2 inhibitors, and pioglitazone are recommended pharmacotherapies for MASLD/MASH management.

If lifestyle changes are not enough, ask your doctor about GLP-1 RAs, SGLT2 inhibitors, or pioglitazone. These medications can help manage metabolic health and reduce liver disease progression.

Physiological levels of reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2), act as essential signaling molecules that augment insulin sensitivity and glucose uptake in skeletal muscle by inhibiting negative regulators like PTP1B and activating Akt.

Do not assume that high-dose antioxidant supplements improve insulin sensitivity. In healthy or early-stage metabolic contexts, your body relies on low levels of oxidative stress (ROS) to signal insulin to move glucose into muscles. Blocking this signal with excessive antioxidants may actually impair glucose uptake and metabolic adaptation.

Mechanistically, GLP-1RA-induced muscle loss is driven by reduced protein intake, negative energy balance, and suppressed mTOR signaling due to lower insulin/IGF-1 levels, rather than direct myotoxicity.

The muscle loss isn't because the drug attacks muscle directly; it's because you eat less, have less energy, and your body's growth signals (like insulin) are lower. This is why eating enough protein and lifting weights is crucial to counteract these natural signals.

Small-molecule GLP-1 receptor agonists (e.g., orforglipron) are pharmacologically inactive in standard wild-type mice due to species-specific receptor binding differences, requiring humanized GLP-1 receptor (hGLP1R) mouse models to accurately predict human metabolic efficacy.

If you are evaluating or using small-molecule GLP-1 drugs (like orforglipron), standard animal testing will not show their effects. These drugs require a humanized receptor to work in mice. This highlights why human clinical trials are essential for this specific class of drugs, as animal models cannot predict their efficacy.

In humanized GLP-1 receptor mice, small-molecule GLP-1 receptor agonists (e.g., orforglipron) produce metabolic effects (weight loss, glucose tolerance) comparable to peptide-based agonists (e.g., semaglutide).

Small-molecule GLP-1 drugs can work as well as peptide drugs in terms of metabolic effects, provided they bind to the correct receptor. This humanized mouse model confirms that oral small-molecule options have the potential to match the efficacy of injectable peptides.

Discontinuation of GLP-1 medications leads to rapid weight regain (up to two-thirds of prior loss) and worsening cardiometabolic health, disproportionately affecting underserved communities.

Stopping GLP-1 medication often leads to regaining up to two-thirds of the weight lost and worsening health. It is crucial to have a sustainable plan for medication access or transition to maintain long-term health.

Each unit increase in baseline BMI is associated with a statistically significant decrease in health utility scores, indicating that higher obesity severity correlates with lower quality of life.

Higher BMI is consistently linked to lower health utility scores. Treating obesity with semaglutide 2.4 mg can reverse this trend, improving quality of life.

Normobaric hypoxia (NH) with acute exposure (5 min) results in lower blood lactate accumulation and reduced muscle oxygenation compared to hypobaric hypoxia (HH) at equivalent oxygen partial pressure, likely due to insufficient time for ventilatory acclimatization.

If using a hypoxia mask (NH), ensure you are exposed to the low oxygen environment for at least 30 minutes before training to mimic the metabolic stress of real altitude (HH). Short exposure (5 mins) may not trigger the same buffering and lactate responses.

Semaglutide promotes sex-dependent adipose tissue remodeling, with females showing more pronounced reductions in visceral fat mass and greater potency in locomotor activity increases compared to males.

Men and women may respond differently to semaglutide. This study suggests women might experience greater reductions in visceral fat and larger increases in physical activity compared to men at similar doses. This highlights the importance of sex-specific considerations in obesity treatment.